Literature DB >> 12406075

Analysis of factor VIII inhibitors in a haemophilia A patient with an Arg593-->Cys mutation using phage display.

Wendy S Bril1, Ellen A M Turenhout, Paul H P Kaijen, Edward N van den Brink, Maria M W Koopman, Marjolein Peters, Jan Voorberg.   

Abstract

We characterized anti-factor VIII antibodies in a mild haemophilia A patient with an Arg593-->Cys mutation in the A2 domain, using V gene phage-display technology. All isolated single-chain variable-domain antibody fragments were directed against residues Arg484-Ile508, a binding site for factor VIII inhibitors in the A2 domain. After a further period of replacement therapy, a transient rise in inhibitor titre was observed. These antibodies were directed against the A2 domain. Activation of a pre-existing pool of B cells, which express antibodies against residues Arg484-Ile508, could explain the rapid anamnestic response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406075     DOI: 10.1046/j.1365-2141.2002.03856.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.

Authors:  E A James; S D van Haren; R A Ettinger; K Fijnvandraat; J A Liberman; W W Kwok; J Voorberg; K P Pratt
Journal:  J Thromb Haemost       Date:  2011-04       Impact factor: 5.824

2.  In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.

Authors:  C L Kempton; J M Soucie; C H Miller; C Hooper; M A Escobar; A J Cohen; N S Key; A R Thompson; T C Abshire
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.